Hjem
Jan Gunnar Hatlebakks bilde

Jan Gunnar Hatlebakk

Professor
  • E-postJan.Hatlebakk@uib.no
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2020. Supplementation with low doses of a cod protein hydrolysate on glucose regulation and lipid metabolism in adults with metabolic syndrome: A randomized, double-blind study. Nutrients. 1-15.
  • 2020. Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome. Medicine.
  • 2020. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 1-11.
  • 2019. Supplementation with cod protein hydrolysate in older adults: A dose range cross-over study. Journal of Nutritional Science (JNS). 1-8.
  • 2019. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Molecular Medicine Reports. 787-794.
  • 2019. Nasal and salivary pepsin as a biomarker for gastro-esophageal reflux in chronic rhinosinusitis. Rhinology Online. 25-31.
  • 2019. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients.
  • 2019. How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). Gut. 1928-1941.
  • 2019. Gastric emptying of low- and high-caloric liquid meals measured using ultrasonography in healthy volunteers. Ultrasound International Open. E27-E33.
  • 2019. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study . Gut. 1-9.
  • 2019. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut.
  • 2019. Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients. 1-13.
  • 2019. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 1-15.
  • 2019. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology. 690-699.
  • 2019. Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food & Nutrition Research. 1-9.
  • 2018. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLOS ONE. 1-17.
  • 2018. The effect of a controlled gluten challenge in a group of patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Neurogastroenterology and Motility. 1-10.
  • 2018. Navigated retrograde endoscopic myotomy (REM) for the treatment of therapy-resistant achalasia. Neurogastroenterology and Motility. 6 sider.
  • 2018. Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: A double-blind cross-over trial. Journal of Nutritional Science (JNS). 9 sider.
  • 2017. The dynamics of the oesophageal squamous epithelium `normalisation´ process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery. Alimentary Pharmacology and Therapeutics. 1339-1349.
  • 2017. Interaction between diet and gastrointestinal endocrine cells. Biomedical Reports. 651-656.
  • 2017. Gastro-oesophageal reflux in patients with chronic rhino-sinusitis investigated with multichannel impedance - pH monitoring. Rhinology. 27-33.
  • 2017. Gastric accommodation in healthy subjects studied by ultrasound, manometry, and impedancemetry. Neurogastroenterology and Motility. 1-9.
  • 2017. Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1331-1339.
  • 2017. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 1-9.
  • 2017. Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years. Scandinavian Journal of Gastroenterology. 11-17.
  • 2017. Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 691-697.
  • 2017. Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports. 2106-2112.
  • 2016. Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy. Clinical Gastroenterology and Hepatology. 678-685.e3.
  • 2016. Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports. 4967-4974.
  • 2016. Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats. Molecular Medicine Reports. 12-20.
  • 2015. Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World Journal of Gastroenterology (WJG). 9577-9587.
  • 2015. Peroral endoscopic pyloromyotomy for primary pyloric stenosis. Endoscopy.
  • 2015. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology and Therapeutics. 1162-1174.
  • 2015. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: A post hoc analysis of the LOTUS trial. Current Medical Research and Opinion. 65-73.
  • 2015. Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides. 12-19.
  • 2014. Stomach antral endocrine cells in patients with irritable bowel syndrome. International Journal of Molecular Medicine. 967-974.
  • 2014. Endocrine cells in the ileum of patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2383-2391.
  • 2014. Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterology Research and Practice. 8 sider.
  • 2014. Do patients with functional chest pain have neuroplastic reorganization of the pain matrix? A diffusion tensor imaging study. Scandinavian Journal of Pain. 85-90.
  • 2014. Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats. Scientific World Journal. 8 sider.
  • 2014. Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regulatory Peptides. 60-65.
  • 2013. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 564-572.
  • 2013. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scandinavian Journal of Gastroenterology. 1010-1017.
  • 2013. Low‑grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Molecular Medicine Reports. 1081-1085.
  • 2013. Evaluation of the usefulness of colonoscopy with mucosal biopsies in the follow-up of TNBS-induced colitis in rats. Molecular Medicine Reports. 446-450.
  • 2013. Colonoscopy with mucosal biopsies in young rats: A model for experimental gastroenterology. Molecular Medicine Reports. 1757-1760.
  • 2013. Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale. Clinical and Experimental Gastroenterology. 101-107.
  • 2013. Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report. BMC Research Notes. 11 sider.
  • 2013. Central response to painful electrical esophageal stimulation in well-defined patients suffering from functional chest pain. Neurogastroenterology and Motility. E718-E727.
  • 2013. Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. European Journal of Gastroenterology and Hepathology. 531-538.
  • 2012. The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). International Journal of Molecular Medicine. 723-731.
  • 2012. Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies. International journal of clinical practice. 897-905.
  • 2012. Randomised clinical trial: a comparison between a GerdQ‐based algorithm and an endoscopy‐based approach for the diagnosis and initial treatment of GERD. Alimentary Pharmacology and Therapeutics.
  • 2012. Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Alimentary Pharmacology and Therapeutics. 1290-1300.
  • 2012. Low Densities of Serotonin and Peptide YY Cells in the Colon of Patients with Irritable Bowel Syndrome. Digestive Diseases and Sciences. 873-878.
  • 2012. Irritable bowel syndrome: the role of gut neuroendocrine peptides. Frontiers in Bioscience (Elite Edition). 2783-2800.
  • 2012. High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World Journal of Gastroenterology (WJG). 6070-6075.
  • 2012. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Alimentary Pharmacology and Therapeutics. 959-971.
  • 2012. Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Digestive Diseases and Sciences. 3154-3159.
  • 2011. Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled anlysis of five European cluster-randomized studies. Therapeutic Advances in Gastroenterology. 11-26.
  • 2011. Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD The LOTUS Randomized Clinical Trial. Journal of the American Medical Association (JAMA). 1969-1977.
  • 2011. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut. 1182-1188.
  • 2010. Sensation evoked by esophageal distension in functional chest pain patients depends on mechanical stress rather than on ischemia. Neurogastroenterology and Motility. 1170-+.
  • 2010. Mechanosensation and Mucosal Blood Perfusion in the Esophagus of Healthy Volunteers Studied with a Multimodal Device Incorporating Laser Doppler Flowmetry and Endosonography. Digestive Diseases and Sciences. 312-320.
  • 2010. Long-Term Outcome of Microscopic Esophagitis in Chronic GERD Patients Treated With Esomeprazole or Laparoscopic Antireflux Surgery in the LOTUS Trial. American Journal of Gastroenterology. 1015-1023.
  • 2010. Endoscopy in gastro-oesophageal reflux disease. Baillière's Best Practice & Research : Clinical Gastroenterology. 775-786.
  • 2009. Mucosal blood flow measurements using laser Doppler perfusion monitoring. World Journal of Gastroenterology (WJG). 198-203.
  • 2009. Management of gastro-oesophageal reflux disease in primary care: a European observational study. Current Medical Research and Opinion. 2777-2784.
  • 2009. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health and Quality of Life Outcomes. 7 sider.
  • 2009. Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health and Quality of Life Outcomes. 8 sider.
  • 2009. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clinical Gastroenterology and Hepatology. 1292-1298.
  • 2008. Standardization of surgical technique in antireflux surgery: The LOTUS trial experience. World Journal of Surgery. 995-998.
  • 2008. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 1207-1213.
  • 2008. Center for drug evaluation and research. Clinical white paper for the CDER-PHRMA-AASLD conference on drug-induced liver disease: A national and global problem. American Journal of Gastroenterology. 20-26.
  • 2007. Medical therapy of gastroesophageal reflux disease. Current Opinion in Gastroenterology. 434-439.
  • 2007. Advanced imaging and visualization in gastrointestinal disorders. World Journal of Gastroenterology (WJG). 1408-1421.
  • 2006. Novel developments in non-erosive and erosive gastroesophageal reflux disease. Current Opinion in Gastroenterology.
  • 2006. Dysphagia in the course of gastro-oesophageal reflux before surgery. Acta Endoscopica. 545-554.
  • 2006. A multimodal laser Doppler and endosonographic distension device for studying mechanosensation and mucosal blood flow in the oesophagus. Neurogastroenterology and Motility. 243-248.
  • 2005. Apotekpersonalets egenvurdering av kompetanse og faglig selvtillit. Norsk Farmaceutisk Tidsskrift. 17-20.
  • 2004. Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: Multicenter study of the gatekeeper reflux repair system. Endoscopy. 682-689.
  • 2004. Diagnostic approach to suspected irritable bowel syndrome. Baillière's Best Practice & Research : Clinical Gastroenterology. 735-746.
  • 2004. Behandling av gastroøsofageal refluks hos gravide. Tidsskrift for Den norske legeforening. 797-798.
  • 2000. Proton pump inhibitors: better before breakfast than without breakfast. Alimentary Pharmacology and Therapeutics. 1267-1272.
  • 2000. Oesophagusstriktur som komplikasjon til gastrøsofageal refluks hos barn. Tidsskrift for Den norske legeforening. 187-189.
  • 2000. Long-term management of gastro-oesophageal reflux disease with omeprazole or open anti-reflux surgery: results of a prospective, randomized clinical trial. European Journal of Gastroenterology and Hepathology. 879-887.
  • 2000. Gastric acidity and acid breakthrough on omeprazole 20mg b.i.d. or lansoprazole 30mg b.i.d. Alimentary Pharmacology and Therapeutics. 709-714.
  • 1999. Therapy for heartburn in primary care patients - an 8 weeks randomized double-blind study of omeprazole versus cisapride and placebo. BMJ. British Medical Journal. 550-553.
  • 1999. The effect of eradication of H.pylori on gastro-oesophageal reflux. Diseases of the esophagus. 915-920.
  • 1999. Spiromycin is comparable to oxytetracycline in eradicating H. pylori when given with ranititine bismuth citrate and metronidazole. Alimentary Pharmacology and Therapeutics. 651-659.
  • 1999. On demand therapy of reflux oesophagitis - a prospective study of symptoms, patient satisfaction and quality of life. Alimentary Pharmacology and Therapeutics. 1035-1040.
  • 1999. Medical therapy: Management of the refractory patient. Gastroenterology Clinics of North America. 847-860.
  • 1999. Lack of effect of acid suppression on gastric atrophy. Nordic GERD Study Group. Gastroenterology. 319-326.
  • 1999. Intragastric distribution and volume estimation of a liquid meal in patients with gastro-oesophageal reflux disease assessed by three-dimensional ultrasonography. Gut. 180.
  • 1999. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. American Journal of Gastroenterology. 1464-1467.
  • 1999. Effect of Omeprazole (PPI) on Ratio of Acid to Nonacid Gastroesophageal Reflux. Studies Using Simultaneous Intraesophageal Impedance and pH Measurement. Gastroenterology. G910.
  • 1999. Effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Alimentary Pharmacology and Therapeutics. 915-920.
  • 1998. Outcome of open anti-reflux surgery as assessed in a Nordic multicentre, prospective clinical trial. The European Journal of Surgery. 751-757.
  • 1998. Obesity and gastroesophageal reflux. Motility. 4-6.
  • 1998. Gastroesophageal reflux in morbid obese patients treated with gastric banding or vertical banded gastroplasty. Annals of Surgery. 51-58.
  • 1998. Gastro-oesophageal reflux disease in primary care - an international study of different treatment strategies with omeprazole. European Journal of Gastroenterology and Hepathology. 119-124.
  • 1998. Endoscopic ultrasound - a new look at achalasia? European Journal of Gastroenterology and Hepathology. 543-545.
  • 1998. Dysphagia in the elderly: Diagnostic approach and clinical management. Clinical Geriatrics. 16-26.
  • 1998. Dilatation therapy for dysphagia in patients with upper esophageal sphincter dysfunction - manometric and symptomatic response. Diseases of the esophagus. 254-259.
  • 1998. Barretts øsofagus. Et økende problem. Tidsskrift for Den norske legeforening. 4100-4103.
  • 1997. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scandinavian Journal of Gastroenterology. 1100-1106.
  • 1997. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Alimentary Pharmacology and Therapeutics. 1093-1099.
  • 1997. Lansoprazole 15 and 30 mg daily in maintenance therapy of reflux oesophagitis. Alimentary Pharmacology and Therapeutics. 365-372.
  • 1997. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 740-747.
  • 1997. Endoscopic grading of reflux oesophagitis: what observations correlate with gastro-oesophagal reflux? Scandinavian Journal of Gastroenterology. 760-765.
  • 1996. Pharmacokinetic optimisation in the treatment of gastrooesophageal reflux disease. Clinical Pharmacokinetics. 386-406.
  • 1996. Lansoprazole 15 and 30 mg daily in maintenanxe therapy of reflux oesophagitis. Alimentary Pharmacology and Therapeutics.
  • 1996. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scandinavian Journal of Gastroenterology. 954-958.
  • 1996. Bismuth-based combination therapy for Heliobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). American Journal of Gastroenterology. 935-941.
  • 1995. Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Alimentary Pharmacology and Therapeutics. 197-200.
  • 1994. Ti dagers trippelkur for Helicobacter pylori-infeksjon og magesår: Status fire uker og ett år etter. Tidsskrift for Den norske legeforening. 2477-2479.
  • 1994. Ti dagers trippelkur for Helicobacter pylori-infeksjon og magesår: Status fire uker og ett år etter. Tidsskrift for Den norske legeforening. 2477-2479.
  • 1994. Prokinetica ved reflukssykdom. Virkningsmekanismer og klinisk effekt. Tidsskrift for Den norske legeforening. 689-692.
  • 1994. Konferanserapport Digestive diseases WEEK 1994. Therapia medica.
  • 1993. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scandinavian Journal of Gastroenterology. 224-228.
Faglig foredrag
  • 2016. Kinetics of microbial community composition in patients with diarrhea-predominant irritable bowel syndrome following faecal microbiota transplantation.
  • 2013. Gravid kvinne med akutt pustebesvær.
Populærvitenskapelig foredrag
  • 1999. Quality of life in the long term management og gastroesophageal reflux disease treated with omeprazole or antireflux surgery.
  • 1999. Gastric accommodation in patients with gastro-oesophageal reflux disease.
  • 1999. Completely opposite gastric accommodation patterns in functional dyspepsia patient and reflux oesophagitis.
Vitenskapelig foredrag
  • 2020. Kvalitetsevaluering av tverrfaglig IBS-poliklinikk .
  • 2020. Kort- og langtidseffekten av lavFODMAP-diett på symptomer og mikrobiota hos pasienter med IBS .
  • 2020. Chromoendoscopy with Iodine-Potassium iodine solution in eosinophilic esophagitis.
  • 2019. Mage-tarmskolen – tverrfaglig internetbehandling ved Irritabel tarmsyndrom .
  • 2019. Effect of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome.
  • 2019. CHROMOENDOSCOPY WITH IODINE-POTASSIUM IODINE SOLUTION IN EOSINOPHILIC ESOPHAGITIS.
  • 2017. Navigated Retrograde Endoscopic Myotomy (REM) for the Treatment of Therapy-Resistant Achalasia.
  • 2016. Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
  • 2016. Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
  • 2015. Per Oral Endoskopisk Pyloromyotomi (POP) for primær pylorusstensose.
  • 2014. Per Oral Endoskpoisk Myotmi (POEM) for behandling av akalasi.
  • 2013. Endoskopisk behandling av tidlig spiserøreskreft.
  • 2000. Intragastric maldistribution in patients with reflux oesophagitis studied by an accurate 3D ultrasound system.
  • 2000. Evaluation of a symptomatic score for the diagnosis of GERD.
  • 1998. On demand therapy of reflux oesophagitis: a study of symptoms, patient satisfaction and quality of life.
  • 1996. Utredning av ikke-kardiale brystsmerter.
  • 1996. Transient LES-relaksasjon ved reflukssykdom.
  • 1994. Lansoprazole and amoxicillin oral suspension in the treatment of peptic ulcer disease.
  • 1994. Follow-up on 227 Patients with Peptic Ulcer Disease One Year after Eradication of Helicobacter Pylori.
  • 1993. Lansoprazole in the treatment of reflux oesophagitis: A survey of clinical studies.
Leder
  • 2017. Editorial: the diminishing returns of normalisation of the oesophageal mucosa-Authors' reply. Alimentary Pharmacology and Therapeutics. 73-74.
Vitenskapelig monografi
  • 2015. Understanding and Controlling the Irritable Bowel.
Fagbok
  • 2012. Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers, Inc..
Populærvitenskapelig artikkel
  • 2014. Per Oral Endoksopisk Myotomi (POEM)for akalasi. NFG-nytt. 4 sider.
  • 2013. Correct use of proton pump inhibitors for gastro-oesophageal reflux disease. Tidsskrift for Den norske legeforening. 43-46.
Kronikk
  • 2000. Heartburn treatment in primary care. Letter to the editor. BMJ. British Medical Journal. 1406.
Brev til redaktøren
  • 2004. Intravenous esomeprazole - Viewpoint. Drugs. 883-883.
Doktorgradsavhandling
  • 2020. Health effects of supplementation with cod protein hydrolysate: Impact on glucose metabolism and appetite in healthy subjects and gut health in irritable bowel syndrome.
  • 2010. Esophageal pain sensation during bag distention - biomechanical or ischemic in origin? : studied by a multi-modal device incorporating laser Doppler flowmetry, endosonography, manometry, and bag distension.
  • 1997. Diagnosis and treatment of uncomplicated reflux oesophagitis. -.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • 2013. Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones. 13 sider.
  • 2005. Ultrasound in Patients with Gastroesophageal Reflux Disease. 30 sider.
  • 1993. Verdi av pH-måling og manometri status 1993. 9 sider.
Leksikonartikkel
  • 1999. The medically refractory patient - when proton pump inhibitors fail. 1. I:
    • 1999. GI in the Next Century - Clinical Advances in Esophageal and Gastrointestinal Disorders.
Sammendrag/abstract
  • 2020. Changes in fecal short-chain fatty acids (SCFA) following fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility.
  • 2018. Interdisciplinary self- help intervention for IBS - eHealth and patient education. Neurogastroenterology and Motility. 182-183.
  • 2018. Effects of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 178-179.
  • 2017. The effect of a controlled gluten challenge in patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Clinical Nutrition. 32-33.
  • 2017. Gluten causes symptom relapse in a small group of patients with suspected non-celiac gluten sensitivity: A randomized, double-blind placebo controlled challenge. Neurogastroenterology and Motility. 68-69.
  • 2017. Effect of faecal microbiota transplantation on the symptoms and gut microbiota in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility. 73-74.
  • 2017. Effect of faecal microbiota transplantation on gut bacterial fermentation products in patients with irritable bowel syndrome. United European Gastroenterology journal. A563-A564.
  • 2016. The Gastric Accomodation Reflex Studied by Ultrasound, Manometry and Impedancemetry in a Pilot Study. United European Gastroenterology journal. 675-675.
  • 2016. Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial. United European Gastroenterology journal. A101-A101.
  • 2016. Kinetics of microbial community composition in patients with diarrhea-predominant irritable bowel syndrome following faecal microbiota transplantation. United European Gastroenterology journal. LB11-LB11.
  • 2016. Effect of fecal microbiota transplantation on the symptoms and duodenal enteroendocrine cells in patients with irritable bowel syndrome. United European Gastroenterology journal. 677-677.
  • 2012. Duodenal mucosal lymphocyte subgroups in patients with persisting abdominal symptoms after Giardia lamblia infection. Neurogastroenterology and Motility. 172-172.
  • 2011. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. International Journal of Molecular Medicine. S10-S10.
  • 2010. Patients with functional chest pain have an increased oesophageal wall tone during bag distension. Scandinavian Journal of Gastroenterology. 45-45.
  • 2009. Mechanosensation and mucosal blood perfusion during bag distension in the esophagus in patients with functional chest pain. Scandinavian Journal of Gastroenterology. 38-38.
  • 2009. Changes in prescriptions dispensed for proton pump inhibitors (PPIs) following new restrictions on reimbursement - a nationwide Norwegian prescription database study. Scandinavian Journal of Gastroenterology. 39-39.
  • 2009. CHANGES IN PRESCRIPTIONS DISPENSED ON PROTON PUMP INHIBITORS (PPIS) FOLLOWING NEW RESTRICTIONS FOR REIMBURSEMENT - A NATIONWIDE NORWEGIAN PRESCRIPTION DATABASE STUDY. Value in Health. A58-A58.
  • 2007. Postprandial symptoms in healthy subjects improve in the left lateral supine position. Scandinavian Journal of Gastroenterology. 24-24.
Poster
  • 2019. OUTCOME OF PER ORAL ENDOSCOPIC MYOTOMY FOR TREATMENT OF ACHALASIA - NORWEGIAN SINGLE CENTER EXPERIENCE WITH MEDIAN FOLLOWING-UP OF 24 MONTHS.
  • 2019. Evaluation of a tertiary, multidisciplinary outpatient clinic for irritable bowel syndrome.
  • 2019. Brain-Gut-Microbiota Interaction in Irritable Bowel Syndrome: A Multidimensional Approach .
  • 2018. Correlations between gut microenvironment and symptoms in patients with diarrhea-predominant irritable bowel syndrome.
  • 1998. H.pylori infection increases nocturnal acid control on proton pump inhibitors.
Errata
  • 2019. Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: A double-blind cross-over trial - CORRIGENDUM. Journal of Nutritional Science (JNS). 1-2.
Vitenskapelig oversiktsartikkel/review
  • 2019. Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). 1-7.
  • 2019. Pathophysiology of idiopathic gastroparesis and implications for therapy. 8-17.
  • 2017. Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel Disease. 5068-5085.
  • 2016. The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. 139-148.
  • 2016. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. 111-122.
  • 2015. The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome.
  • 2014. Is irritable bowel syndrome an organic disorder? 384-400.
  • 2014. Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. 435-443.
  • 2014. Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (Review). 363-371.
  • 2014. Chronic constipation and treatment options (Review). 3-8.
  • 2013. The role of peptide YY in gastrointestinal diseases and disorders (Review). 275-282.
  • 2013. Gastroesophageal Reflux and Rhinosinusitis. 218-223.
  • 2013. Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review). 263-270.
  • 2012. Irritable bowel syndrome: treatment options. 591-600.
  • 2008. Clinical trial design in adult reflux disease: a methodological workshop. 107-126.
Faglig kapittel
  • 2017. Sykdommer i øsofagus. 326-333. I:
    • 2017. Indremedisin I & II. Forlag Vett & Viten.

Se fullstendig oversikt over publikasjoner i CRIStin.